This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Summy, J. M. Articles by Gallick, G. E. Search for Related Content PubMed PubMed Citation Articles by Summy, J. M. Articles by Gallick, G. E.

¹ Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas and ² ARIAD Pharmaceuticals, Inc., Cambridge, Massachusetts

Requests for reprints: Gary E. Gallick, Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Box 179, Smith Research Building, 7777 Knight Road, Houston, TX 77054. Phone: 713-563-4919; Fax: 713-563-5489. E-mail: ggallick{at}mdanderson.org

c-Src is frequently activated in human malignancies, including colon, breast, and pancreatic carcinomas. Several recent studies have shown that activation of Src family kinases leads to tumor progression and metastasis by increasing cellular migration and invasion, promoting cell growth and survival, and deregulating expression of proangiogenic molecules. Therefore, selective inhibitors of Src are being developed for cancer therapy. In this study, we characterize the biological effects of the novel ATP-based Src family kinase inhibitor, AP23846, in tumor cells with high Src activity. As a lead compound, AP23846 is a potent c-Src kinase inhibitor (IC₅₀ 0.5 nmol/L in vitro, 10-fold more potent than PP2, the most widely used commercially available Src family kinase inhibitor). At concentrations of 1 µmol/L, AP23846 led to complete Src inhibition for 48 hours in cells. No cytotoxicity was observed under these conditions, although proliferation rates were slower. Therefore, this was an excellent inhibitor to examine Src-regulated signaling pathways in tumor cells. AP23846 reduced cellular migration, vascular endothelial growth factor, and interleukin-8 in a dose-dependent fashion in pancreatic adenocarcinoma cells grown in vitro. Correspondingly, cell culture supernatants from L3.6pl pancreatic adenocarcinoma cells pretreated with AP23846 failed to promote migration of hepatic endothelial cells in vitro and failed to support angiogenesis into gel foams implanted s.c. in mice in vivo. These results suggest that Src inhibitors affect biological properties of tumor progression and may be useful as cancer therapeutic agents in more advanced disease. [Mol Cancer Ther 2005;4(12):1900–11]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: J.M. Summy and J.G. Trevino contributed equally to this work.

³ Unpublished data.

Received 5/26/05; revised 9/13/05; accepted 10/19/05.